Mahmoudi E, Lin P, Khan A, Kamdar N, Peterson MD. Potentially preventable hospitalizations among adults with pediatric-onset disabilities. Mayo Clin Proc. 2022 Dec;97(12):2226-35. doi: 10.1016/j.mayocp.2022.07.026.
Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Lairson DR, Parikh RC, Cormier JN, Wenyaw C, Du XL. Cost-utility analysis of treatments for advanced non-small cell lung cancer. Am J Pharm Benefits. 2015 Nov;7(6):271-9.
Lopes M, Chulikavit M, Parikh R, Stern L, Liu Z, Rogerio J. Budget impact of everolimus in treating metastatic renal cell carcinoma. Am J Pharm Benefits. 2012;4(Special Issue):sp41-8.
Mintz ML, Yawn BP, Mannino DM, Donohue JF, Hanania NA, Grellet CA, Gilsenan AW, McLeod LD, Dalal AA, Raphiou IH, Prillaman BA, Crater GD, Cicale MJ, Mapel DW. Prevalence of airway obstruction assessed by lung function questionnaire. Mayo Clin Proc. 2011 May 1;86(5):375-81.